Literature DB >> 22341272

Targeted antimicrobial prophylaxis using rectal swab cultures in men undergoing transrectal ultrasound guided prostate biopsy is associated with reduced incidence of postoperative infectious complications and cost of care.

Aisha K Taylor1, Teresa R Zembower, Robert B Nadler, Marc H Scheetz, John P Cashy, Diana Bowen, Adam B Murphy, Elodi Dielubanza, Anthony J Schaeffer.   

Abstract

PURPOSE: We evaluated targeted antimicrobial prophylaxis in men undergoing transrectal ultrasound guided prostate biopsy based on rectal swab culture results.
MATERIALS AND METHODS: From July 2010 to March 2011 we studied differences in infectious complications in men who received targeted vs standard empirical ciprofloxacin prophylaxis before transrectal ultrasound guided prostate biopsy. Targeted prophylaxis used rectal swab cultures plated on selective media containing ciprofloxacin to identify fluoroquinolone resistant bacteria. Patients with fluoroquinolone susceptible organisms received ciprofloxacin while those with fluoroquinolone resistant organisms received directed antimicrobial prophylaxis. We identified men with infectious complications within 30 days after transrectal ultrasound guided prostate biopsy using the electronic medical record.
RESULTS: A total of 457 men underwent transrectal ultrasound guided prostate biopsy, and of these men 112 (24.5%) had rectal swab obtained while 345 (75.5%) did not. Among those who received targeted prophylaxis 22 (19.6%) men had fluoroquinolone resistant organisms. There were no infectious complications in the 112 men who received targeted antimicrobial prophylaxis, while there were 9 cases (including 1 of sepsis) among the 345 on empirical therapy (p=0.12). Fluoroquinolone resistant organisms caused 7 of these infections. The total cost of managing infectious complications in patients in the empirical group was $13,219. The calculated cost of targeted vs empirical prophylaxis per 100 men undergoing transrectal ultrasound guided prostate biopsy was $1,346 vs $5,598, respectively. Cost-effectiveness analysis revealed that targeted prophylaxis yielded a cost savings of $4,499 per post-transrectal ultrasound guided prostate biopsy infectious complication averted. Per estimation, 38 men would need to undergo rectal swab before transrectal ultrasound guided prostate biopsy to prevent 1 infectious complication.
CONCLUSIONS: Targeted antimicrobial prophylaxis was associated with a notable decrease in the incidence of infectious complications after transrectal ultrasound guided prostate biopsy caused by fluoroquinolone resistant organisms as well as a decrease in the overall cost of care. Copyright Â
© 2012 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22341272     DOI: 10.1016/j.juro.2011.11.115

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  74 in total

Review 1.  The emerging threat of multidrug-resistant Gram-negative bacteria in urology.

Authors:  Hosam M Zowawi; Patrick N A Harris; Matthew J Roberts; Paul A Tambyah; Mark A Schembri; M Diletta Pezzani; Deborah A Williamson; David L Paterson
Journal:  Nat Rev Urol       Date:  2015-09-01       Impact factor: 14.432

2.  Peri-procedural povidone-iodine rectal preparation reduces microorganism counts and infectious complications following ultrasound-guided needle biopsy of the prostate.

Authors:  Justin R Gyorfi; Christopher Otteni; Kevin Brown; Amar Patel; Kathleen Lehman; Brett E Phillips; Kalyan Dewan; Girish Kirimanjeswara; Jay D Raman
Journal:  World J Urol       Date:  2014-03-30       Impact factor: 4.226

3.  Infective complications in patients after transrectal ultrasound-guided prostate biopsy and the role of ciprofloxacin resistant Escherichia coli colonization in rectal flora.

Authors:  Mustafa Bilal Hamarat; Fatih Tarhan; Rahim Horuz; Gülfem Akengin Öcal; Mehmet Kutlu Demirkol; Alper Kafkaslı; Özgür Yazıcı
Journal:  Turk J Urol       Date:  2017-05-03

4.  [Infection and sepsis prevention in prostate biopsy].

Authors:  F M E Wagenlehner; A Pilatz; P Waliszewski; T Dansranjavin; W Weidner
Journal:  Urologe A       Date:  2013-10       Impact factor: 0.639

5.  An antimicrobial prophylaxis protocol using rectal swab cultures for transrectal prostate biopsy.

Authors:  Stephen J Summers; Darshan P Patel; Blake D Hamilton; Angela P Presson; Mark A Fisher; William T Lowrance; Andrew W Southwick
Journal:  World J Urol       Date:  2015-05-03       Impact factor: 4.226

6.  CUA Guidelines on antibiotic prophylaxis for urologic procedures.

Authors:  Marko Mrkobrada; Ivan Ying; Stephanie Mokrycke; George Dresser; Sameer Elsayed; Varunkumar Bathini; Erin Boyce; Patrick Luke
Journal:  Can Urol Assoc J       Date:  2015 Jan-Feb       Impact factor: 1.862

7.  Sepsis: Prophylactic antibiotic for prostate biopsy: the carbapenem gamble.

Authors:  Deepak K Pruthi; Michael A Liss
Journal:  Nat Rev Urol       Date:  2017-05-23       Impact factor: 14.432

8.  Cost-effectiveness of MR Imaging-guided Strategies for Detection of Prostate Cancer in Biopsy-Naive Men.

Authors:  Shivani Pahwa; Nicholas K Schiltz; Lee E Ponsky; Ziang Lu; Mark A Griswold; Vikas Gulani
Journal:  Radiology       Date:  2017-05-17       Impact factor: 11.105

9.  Febrile infection in post-prostate biopsy: results of a ten-year single-institution study in South Taiwan.

Authors:  Yuh-Shyan Tsai; Chia-Hong Chen; Yeong-Chin Jou; Wen-Horng Yang; Chien-Chen Chang; Tzong-Shin Tzai
Journal:  Surg Infect (Larchmt)       Date:  2013-11-27       Impact factor: 2.150

10.  Increase of prostate biopsy-related bacteremic complications in southern Finland, 2005-2013: a population-based analysis.

Authors:  K Lahdensuo; A Rannikko; V-J Anttila; A Erickson; A Pätäri-Sampo; M Rautio; H Santti; E Tarkka; M Vaara; K Huotari
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-08-16       Impact factor: 5.554

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.